Dimagi, Inc.

Speaking session and poster at the 2023 American Public Health Association (APHA) conference will also highlight successful use cases from the state of Vermont CAMBRIDGE, Mass., Nov. 2, 2023 /PRNewswire/ -- Dimagi, a technology partner for public and community health, will present on its innovative programs deployed across various state partnerships at the 2023 American Public Health Association (APHA) conference. At the show, which will explore obstacles and opportunities in public health, Dimagi will discuss best practices and learned strategies from two successful programs in Vermont, which address barriers to care for individuals struggling with substance use disorder (SUD) and homelessness. SUD affects more than 20 million Americans over the age of 12, and recent data shows that the number of homeless individuals in the U.S. has reached an all-time-high. Dimagi will expand upon current industry-leading approaches around these topics by presenting case studies of cutting-edge state partnerships that have made a strong positive impact in the remote treatment of SUD and in meeting the needs of unhoused populations in Vermont: Reducing housing insecurity among Vermont residents through a unified, tech-driven screening approach: This oral presentation from Lily Olson, Sr. Director, U.S. Public Health Strategy, will explore an ambitious project led by Dimagi and four Vermont state agencies that enabled care teams to share data and speed coordination of essential care for Vermont's homeless population. The presentation will take place at 2:30 p.m. EST on Tuesday, November 14 in M4 – Grand Ballroom A as part of APHA's caucus on homelessness program. Boosting connectivity to ease care-access barriers — and improve MAT outcomes: This poster will outline the successful results of a three-year pilot program between Dimagi's SureAdhere Video-Observed Therapy solution and the state of Vermont. The program uses a patient-facing mobile app to remotely capture daily medication ingestion and enables rapid triage and remote follow-up with patients who needed extra support. The poster will be presented as part of APHA's Opioids Poster Session 1 from 1:00 – 2:00 p.m. on Sunday, November 12 in the Poster Sessions area. In addition to presenting these programs, Dimagi team members will be onsite in booth #142, and available to discuss these successes and other ways the organization has partnered with public health organizations in 24 states to improve health across the U.S. About Dimagi Dimagi is a global social enterprise that powers impactful public health work through innovative and scalable digital solutions and services. Founded in 2002 out of MIT and Harvard Medical School's joint division Health Science Tech, Dimagi is globally recognized as the maker of CommCare, the most widely-deployed digital platform that empowers a range of critical health programs, from public health and behavioral health to infectious disease management and more. CommCare has provided proven, customizable applications to over 3,000 projects worldwide, helping thousands of frontline workers, governments and NGOs deliver care and enable stronger health outcomes in their communities. One of the first Certified B Corporations established in Massachusetts, Dimagi has partnered with 24 states across the U.S. to improve public health initiatives domestically. Learn more at SOURCE Dimagi, Inc.

Digital template application powered by CommCare for investigating monkeypox cases and tracing contacts to be offered free for 6 months to control outbreaks CAMBRIDGE, Mass., Sept. 7, 2022 /PRNewswire/ -- Dimagi, a global social impact organization and leader in frontline health technology, announced that it will be offering a free monkeypox case management solution to any US public health department beginning September 12, 2022. The solution will come with a pre-configured case investigation and contact tracing (CICT) application built on the open-source platform, CommCare. Dimagi will provide 6 months of free CommCare Enterprise Premier subscription along with the application to support uptake. Continue Reading As of September 1, 2022, the US monkeypox crisis has climbed to over 19,000 cases. Public health departments are often overwhelmed with the important work of responding to infectious disease outbreaks—and for good reason. Many of these departments have been underfunded, and as a result, their resources have been limited. Having a free pre-built solution can help public health departments use their limited resources to respond more effectively. Dimagi solution for investigating monkeypox cases & tracing contacts to be offered free to US public health departments Tweet this In addition to investigating cases, setting up contact tracing plays a vital role in helping to slow the spread of monkeypox. In a recent article published by Duke University about monkeypox, infectious disease specialist, Dr. Cameron Wolfe mentions, "tracing is something we did at the beginning of COVID. It's really important here. People may not know they've been exposed. This is a close contact, skin-to-skin related condition so remaining at home during that time is really crucial." With the scalability of the evidence-based CommCare platform, Dimagi was able to build a monkeypox solution quickly. The solution will be available on any web browser and comes with pre-built user roles and automated workflows so users can immediately begin using it as part of their CICT workstream. Optional symptom monitoring using SMS will also be available. The data that is collected can be easily exported for CDC reporting. Getting started is simple with no upfront cost and on-demand, self-guided training to launch the solution out-of-the-box. "Dimagi has supported numerous public health departments in responding to various infectious disease emergencies - from Ebola and Zika, and most recently, COVID-19 in 40 countries. From these experiences, we've seen firsthand how important it is for technology like ours to support overburdened healthcare systems in the best ways we can," said Jonathan Jackson, Dimagi's CEO and Co-Founder. "We do this by rapidly building applications departments can use for free, all leveraging a shared data framework on CommCare. Our teams are working on these efforts both for monkeypox and other infectious diseases that countries face." To learn more visit our website. About Dimagi Dimagi is a global social impact organization, working since 2002 towards our vision of a world where everyone has access to the services they need to thrive. Headquartered in Cambridge, Massachusetts and with teams in India, South Africa, Senegal, and around the world, Dimagi partners with governments, NGOs, and foundations to amplify their frontline impact through scalable digital solutions and expert services. Our open-source flagship product, CommCare, is the world's most widely-used data collection and service delivery platform, and has been used by more than one million people in 130 countries. An evidence base of more than 90 peer-reviewed publications has shown that equipping Frontline Workers with CommCare improves performance, quality of care delivered, and client health outcomes. Learn more at dimagi.com. SOURCE Dimagi, Inc.

CAMBRIDGE, Mass., March 2, 2022 – Dimagi, a leader in frontline digital solutions, today announced that it is acquiring SureAdhere, a mobile technology company pioneering video directly observed therapy (VDOT or VOT). This acquisition will strengthen Dimagi’s digital solutions for Frontline Workers and pave the way for new virtual care models and a more robust digital ecosystem for clinical trials. Dimagi is known for its open source CommCare platform, which equips Frontline Workers in 130 countries with digital solutions that not only help them deliver better services, but also make their jobs better. SureAdhere was born from a similar aim. Founded in 2014, SureAdhere’s technology augments traditional DOT with an offline-capable asynchronous video platform for affected people and providers to support TB treatment adherence. “As a mission-driven company, our goal is to improve frontline service delivery with technology that meets public health needs globally and in the United States,” shared Jonathan Jackson, Dimagi’s CEO. “What started as a conversation with SureAdhere about partnering quickly turned into a conversation about an acquisition, which will strengthen Dimagi’s portfolio of solutions for health service delivery and create a path to scaling the impact of both organizations. We have been so impressed with SureAdhere’s technology and team, and we are thrilled to welcome them to Dimagi.” “We began this journey in an effort to make both people living with tuberculosis (TB) and healthcare workers’ lives better. With DOT, which has been the standard of care for TB, public health workers were meeting with people daily to monitor medication adherence, exposing them to risk of infection and placing a huge cost burden on the system.” shared Dr. Kelly Collins, SureAdhere’s CEO. “This approach is expensive, inefficient, and often fails to empower people in their own care. Our founding team felt there was a better way to successfully manage adherence while also enabling differentiated care. Our technology helps to triage the work of a health worker so they can quickly identify and connect with those at highest risk for poor outcomes.” Dimagi’s mission of building and scaling sustainable, high-impact digital solutions to amplify Frontline Workers and programs resonates with SureAdhere’s. Additional areas of alignment between the two social enterprises include: SureAdhere’s VOT platform is currently accessible in over 350 jurisdictions across the United States and 24 additional countries spanning Central America, the Caribbean, Europe, Sub-Saharan Africa, and Central and Southeast Asia. A new study in JAMA Network Open shows that electronic DOT is non-inferior to in-person DOT for TB treatment adherence, which will likely strengthen the CDC’s current guidance on eDOT for TB in the US and support further uptake of VOT as a chosen standard of care for TB treatment support globally. “While we began SureAdhere to scale technology for video observation and reduce the burden of DOT, our technology has evolved towards a model of whole person support and engagement over treatment monitoring. People care about their own health – as do providers. We believe digital tools can support the shared goal of health and wellness without the focus on monitoring and adherence,” said Collins. Starting in early 2020, Dimagi rapidly expanded its presence in the United States, working with State and local governments on public health programs for COVID-19 response, Behavioral Healthcare and other emerging use cases. More and more programs in the US are incorporating virtual care as a component of a larger care model, creating opportunities for Dimagi and SureAdhere in this market. “There are many gaps in access to virtual care tools among vulnerable and underserved communities. SureAdhere has just scratched the surface on the many potential applications of our digital engagement technology: clinical research and drug development, mental and behavioral health support, substance use disorder, and HIV prevention to name a few,” shared Collins. “However, we are a small team with limited bandwidth. Dimagi has built an incredibly talented global team. This partnership opens up the possibility to grow SureAdhere’s impact on TB, launch new use cases, and focus on our shared mission of using technology to improve care delivery systems globally.” The entire SureAdhere team will be joining Dimagi, creating a new subdivision focused on the VOT portfolio. Dr. Kelly Collins will oversee the team as Global Director of Digital Adherence, under CEO Jonathan Jackson’s leadership. Current SureAdhere customers can expect no changes to their existing VOT services and the team looks forward to releasing several platform improvements in 2022.